心内科医生在安德森-法布里病管理中的角色
安德森-法布里病(AFD)是一种溶酶体贮积病,以心脏细胞糖脂蓄积为特征,表现为一种特殊类型的肥厚型心肌病(HCM),高达1%的HCM患者实际患有AFD。随着针对肌节性HCM及其基因模拟病的靶向治疗出现,及时鉴别诊断至关重要。AFD治疗领域正快速演变,提供越来越有效的疾病修饰治疗选择,但诊断仍具挑战性,尤其是在无全身警示标志、以显著或孤立心脏受累的非经典型表型中。本综述旨在重新定义心内科医生在当代AFD临床诊疗和药物研发主要决策节点中的角色。
要点
- 高达1%的HCM患者实际患有AFD,需及时鉴别诊断。
- AFD诊断困难,非经典型表型可无全身警示标志。
- 心内科医生在AFD多学科团队中起决定性作用。
核心结论
- 心内科医生在AFD的鉴别诊断、并发症预防及疾病特异性治疗时机评估中起决定性作用。
研究设计与样本
- 本综述旨在重新定义心内科医生在当代AFD临床诊疗和药物研发主要决策节点中的角色。
主要发现
- 高达1%的HCM患者实际患有AFD;AFD可表现为特殊类型的肥厚型心肌病。
- AFD诊断可能困难,尤其是无全身警示标志的非经典型表型。
- 晚期启动治疗导致心脏受累加重,是男女患者发病和死亡的主要原因。
临床怎么用
- AFD患者的最佳管理需要 dedicated 多学科团队,中心内科医生发挥决定性作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anderson-Fabry disease (AFD) is a lysosomal storage disorder characterized by glycolipid accumulation in cardiac cells, associated with a peculiar form of hypertrophic cardiomyopathy (HCM). Up to 1% of patients with a diagnosis of HCM indeed have AFD. With the availability of targeted therapies for sarcomeric HCM and its genocopies, a timely differential diagnosis is essential. Specifically, the therapeutic landscape for AFD is rapidly evolving and offers increasingly effective, disease-modifying treatment options. However, diagnosing AFD may be difficult, particularly in the non-classic phenotype with prominent or isolated cardiac involvement and no systemic red flags. For many AFD patients, the clinical journey from initial clinical manifestations to diagnosis and appropriate treatment remains challenging, due to late recognition or utter neglect. Consequently, late initiation of treatment results in an exacerbation of cardiac involvement, representing the main cause of morbidity and mortality, irrespective of gender. Optimal management of AFD patients requires a dedicated multidisciplinary team, in which the cardiologist plays a decisive role, ranging from the differential diagnosis to the prevention of complications and the evaluation of timing for disease-specific therapies. The present review aims to redefine the role of cardiologists across the main decision nodes in contemporary AFD clinical care and drug discovery.
引用
- Pieroni M, Namdar M, Olivotto I, et al. Anderson-Fabry disease management: role of the cardiologist. Eur Heart J. 2024. PMID: 38486361. doi:10.1093/eurheartj/ehae148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。